Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.

Article  PubMed  Google Scholar 

Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: current and future treatment. Clin Respir J. 2022;16:84–96.

Article  PubMed  PubMed Central  Google Scholar 

Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18–47.

Article  PubMed  PubMed Central  Google Scholar 

Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 1997;111:51–7.

Article  CAS  PubMed  Google Scholar 

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

Article  PubMed  Google Scholar 

Mayr CH, Simon LM, Leuschner G, Ansari M, Schniering J, Geyer PE, Angelidis I, Strunz M, Singh P, Kneidinger N, et al. Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Mol Med. 2021;13:e12871.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu Z, Chen H, Ke S, Mo L, Qiu M, Zhu G, Zhu W, Liu L. Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis. Sci Rep. 2023;13:16559.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clynick B, Corte TJ, Jo HE, Stewart I, Glaspole IN, Grainge C, Maher TM, Navaratnam V, Hubbard R, Hopkins PMA et al. Biomarker signatures for progressive idiopathic pulmonary fibrosis. Eur Respir J 2022, 59.

Ji H, Song X, Lv X, Shao F, Long Y, Song Y, Song W, Qiao P, Gai Y, Jiang D, Lan X. [(68)Ga]FAPI PET for imaging and treatment monitoring in a preclinical model of pulmonary fibrosis: comparison to [(18)F]FDG PET and CT. Pharmaceuticals (Basel) 2024, 17.

Meissner HH, Soo Hoo GW, Khonsary SA, Mandelkern M, Brown CV, Santiago SM. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197–202.

Article  PubMed  Google Scholar 

Justet A, Laurent-Bellue A, Thabut G, Dieudonne A, Debray MP, Borie R, Aubier M, Lebtahi R, Crestani B. [(18)F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18:74.

Article  PubMed  PubMed Central  Google Scholar 

Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR et al. [(68) Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging 2022.

Mannes PZ, Adams TS, Farsijani S, Barnes CE, Latoche JD, Day KE, Nedrow JR, Ahangari F, Kaminski N, Lee JS, Tavakoli S. Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1. Sci Adv. 2024;10:eadm9817.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pommerolle L, Beltramo G, Biziorek L, Truchi M, Dias AMM, Dondaine L, Tanguy J, Pernet N, Goncalves V, Bouchard A et al. CD206(+) macrophages are relevant non-invasive imaging biomarkers and therapeutic targets in experimental lung fibrosis. Thorax 2024.

Brody SL, Gunsten SP, Luehmann HP, Sultan DH, Hoelscher M, Heo GS, Pan J, Koenitzer JR, Lee EC, Huang T, et al. Chemokine receptor 2-targeted Molecular Imaging in Pulmonary Fibrosis. A clinical trial. Am J Respir Crit Care Med. 2021;203:78–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, Guo HH, Haywood T, Abou-Elkacem L, Baratto L, et al. Evaluation of integrin alphavbeta6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nat Commun. 2019;10:4673.

Article  PubMed  PubMed Central  Google Scholar 

Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P et al. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med 2017, 9.

Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: first-in-human studies. Am J Respir Crit Care Med. 2019;200:258–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee HJ, Bernau K, Harr TJ, Rosenkrans ZT, Kessler GA, Stott K, Oler AT, Rahar B, Zhu T, Medina-Guevara Y, et al. [(64)Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis. Sci Adv. 2024;10:eadj1444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jailkhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, Jiang Z, Ploegh HL, Hynes RO. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116:14181–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saunders JT, Schwarzbauer JE. Fibronectin matrix as a scaffold for procollagen proteinase binding and collagen processing. Mol Biol Cell. 2019;30:2218–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sottile J, Hocking DC. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell. 2002;13:3546–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrera J, Forster C, Pengo T, Montero A, Swift J, Schwartz MA, Henke CA, Bitterman PB. Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis. JCI Insight 2019, 4.

Herrera JA, Dingle L, Montero MA, Venkateswaran RV, Blaikley JF, Lawless C, Schwartz MA. The UIP/IPF fibroblastic focus is a collagen biosynthesis factory embedded in a distinct extracellular matrix. JCI Insight 2022, 7.

Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397–419.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomasini-Johansson BR, Kaufman NR, Ensenberger MG, Ozeri V, Hanski E, Mosher DF. A 49-residue peptide from adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly. J Biol Chem. 2001;276:23430–9.

Article  CAS  PubMed  Google Scholar 

Maurer LM, Tomasini-Johansson BR, Ma W, Annis DS, Eickstaedt NL, Ensenberger MG, Satyshur KA, Mosher DF. Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes. J Biol Chem. 2010;285:41087–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zbyszynski P, Tomasini-Johansson BR, Peters DM, Kwon GS. Characterization of the PEGylated Functional Upstream Domain peptide (PEG-FUD): a potent fibronectin assembly inhibitor with potential as an anti-fibrotic therapeutic. Pharm Res. 2018;35:126.

Article  PubMed  PubMed Central  Google Scholar 

Zbyszynski P, Toraason I, Repp L, Kwon GS. Probing the subcutaneous absorption of a PEGylated FUD peptide nanomedicine via in vivo fluorescence imaging. Nano Converg. 2019;6:22.

Article  PubMed  PubMed Central  Google Scholar 

Lee HJ, Gari MK, Inman DR, Rosenkrans ZT, Burkel BM, Olson AP, Engle JW, Hernandez R, Ponik SM, Kwon GS. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer. J Control Release. 2022;350:284–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta N, Bernau K, Lee HJ, Oler AT, Rahar B, Harr TJ, Stott K, Zhu T, Sandbo NS. Kwon: Fibronectin (FN) binding efficacy of PEGylated FUD (PEG-FUD) peptide in bleomycin treated animal model for the treatment of pulmonary fibrosis. American Assoc Pharma Scie. 2023.

Bernau K, Gupta TJHN, Stott K, Rahar B, Oler AT, Medina-Guevara Y, Lee HJ, Gari MK, Burkel BM, Tomasini B, Ponik SM, Engle J, Hernandez R, Kwon G, Sandbo NK. PEG-FUD, A Promising Probe for Pulmonary Fibrosis, Targets the Pro-fibrotic Phase of Disease. American Thoracic Society Conference 2024, B29 Biomarkers and new therapeutics targets in lung Fibrosis.

Stott K, Oler HJLAT, Rahar B, Harr TJ, Medina-Guevara Y, Gupta N, Holbert K, Rosenkrans Z, Kwon GS, Engle JW, Hernandez R, Sandbo N, Bernau K. Fibrotic precision-cut lung slices for assessment of radiolabeled probe targeting. Pulmonary Fibros Foundation Summit 2023.

Filla MS, Dimeo KD, Tong T, Peters DM. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Exp Eye Res. 2017;165:7–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer LM, Ma W, Eickstaedt NL, Johnson IA, Tomasini-Johansson BR, Annis DS, Mosher DF. Ligation of the fibrin-binding domain by beta-strand addition is sufficient for expansion of soluble fibronectin. J Biol Chem. 2012;287:13303–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun H, England CG, Hernandez R, Graves SA, Majewski RL, Kamkaew A, Jiang D, Barnhart TE, Yang Y, Cai W. ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. Eur J Nucl Med Mol Imaging. 2016;43:2169–79.

Article